{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:07:42Z","timestamp":1791659262810,"version":"4.3.4"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clim.2022.108976","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T20:27:52Z","timestamp":1646771272000},"page":"108976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Revisiting immunological and clinical aspects of membranous nephropathy"],"prefix":"10.1016","volume":"237","author":[{"given":"Israel","family":"Nieto-Ga\u00f1\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Iturrieta-Zuazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Carrasco-Sayalero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ki.1991.242","article-title":"Elevated urinary excretion of the C5b-9 complex in membranous nephropathy","volume":"40","author":"Schulze","year":"1991","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJMe0903343","article-title":"Human idiopathic membranous nephropathy \u2014 a mystery solved?","volume":"361","author":"Glassock","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2022.108976_bb0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.clim.2022.108976_bb0020","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0025","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain containing 7A specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2022.108976_bb0030","series-title":"The Incidence of Primary Glomerulonephritis Worldwide: A Systematic Review of the Literature","first-page":"414","author":"Mcgrogan","year":"2011"},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0035","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"1119","key":"10.1016\/j.clim.2022.108976_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/postgradmedj-2018-135729","article-title":"Primary membranous nephropathy: comprehensive review and historical perspective","volume":"95","author":"Keri","year":"2019","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0060","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.clim.2022.108976_bb0065","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","article-title":"Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association","volume":"70","author":"Lefaucheur","year":"2006","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0070","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.clim.2022.108976_bb0080","series-title":"Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy","first-page":"697","author":"Polanco","year":"2010"},{"issue":"9981","key":"10.1016\/j.clim.2022.108976_bb0085","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0090","first-page":"2615","article-title":"Clinicopathological features and prognosis in patients with idiopathic membranous nephropathy with hypertension","volume":"19","author":"Lu","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.clim.2022.108976_bb0095","first-page":"S96","article-title":"Pathogenetic concepts of membranous glomerulopathy (MGN)","volume":"13","author":"Kerjaschki","year":"2000","journal-title":"J. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey","volume":"56","author":"Glassock","year":"2010","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2009121220","article-title":"Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy","volume":"21","author":"Ronco","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000185130","article-title":"Idiopathic membranous nephropathy in 2 twin brothers","volume":"50","author":"Vangelista","year":"1988","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0115","doi-asserted-by":"crossref","first-page":"c10","DOI":"10.1159\/000112466","article-title":"Familial membranous nephropathy: an X-linked genetic susceptibility?","volume":"108","author":"Bockenhauer","year":"2008","journal-title":"Nephron. Clin. Pract."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI110469","article-title":"Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen","volume":"69","author":"Border","year":"1982","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000184336","article-title":"Idiopathic membranous nephropathy in two brothers","volume":"46","author":"Sato","year":"1987","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0130","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0022-3476(05)80391-9","article-title":"Membranous nephropathy in two human leukocyte antigen-identical brothers","volume":"123","author":"Elshihabi","year":"1993","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund\u2019s adjuvants and rat kidney suspensions","volume":"100","author":"Heymann","year":"1959","journal-title":"Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0145","first-page":"502","article-title":"Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis","volume":"38","author":"Van Damme","year":"1978","journal-title":"Lab. Investig."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0150","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1172\/JCI109248","article-title":"Experimental glomerulonephritis in the isolated perfused rat kidney","volume":"62","author":"Couser","year":"1978","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.clim.2022.108976_bb0155","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1681\/ASN.2007030342","article-title":"Intramolecular epitope spreading in Heymann nephritis","volume":"18","author":"Shah","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0160","doi-asserted-by":"crossref","first-page":"F660","DOI":"10.1152\/ajprenal.00437.2004","article-title":"Experimental membranous nephropathy redux","volume":"289","author":"Cybulsky","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"62A","key":"10.1016\/j.clim.2022.108976_bb0165","article-title":"Membranous nephropathy-associated anti-phospholipase A2 receptor IgG4 autoantibodies activate the lectin comple- ment pathway","volume":"22","author":"Ma H","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025065","article-title":"Receptor-mediated endocytosis of \u03b1-galactosidase a in human podocytes in fabry disease","volume":"6","author":"Prabakaran","year":"2011","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.clim.2022.108976_bb0175","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti\u2013neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2022.108976_bb0180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ncpneph0198","article-title":"Mechanisms of disease: alloimmunization in renal diseases","volume":"2","author":"Ronco","year":"2006","journal-title":"Nat. Clin. Pract. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.157.1.155","article-title":"Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens","volume":"157","author":"Platt","year":"1983","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0090-1229(85)90141-2","article-title":"Ontogenesis of the glomerular C3b receptor (CR1) in fetal human kidney","volume":"37","author":"Appay","year":"1985","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"9441","key":"10.1016\/j.clim.2022.108976_bb0195","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(04)17142-0","article-title":"Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies","volume":"364","author":"Debiec","year":"2004","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0200","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1681\/ASN.2004121080","article-title":"Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization","volume":"16","author":"Ronco","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ki.2014.381","article-title":"Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies","volume":"87","author":"Vivarelli","year":"2015","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00467-006-0203-6","article-title":"Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring","volume":"21","author":"Nortier","year":"2006","journal-title":"Pediatr. Nephrol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K","article-title":"The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function","volume":"23","author":"Turner","year":"2001","journal-title":"Bioessays"},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0220","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1003066","article-title":"PLA2R autoantibodies and recurrent membranous nephropathy after transplantation","volume":"363","author":"Stahl","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0225","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1600-6143.2011.03957.x","article-title":"Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation","volume":"12","author":"Blosser","year":"2012","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0230","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/j.1600-6143.2011.03643.x","article-title":"Autoantibodies specific for the phospholipase A2 receptor in recurrent andDe Novomembranous nephropathy","volume":"11","author":"Debiec","year":"2011","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"12","key":"10.1016\/j.clim.2022.108976_bb0235","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1681\/ASN.2012060577","article-title":"Recurrent membranous nephropathy in an allograft caused by IgG3\u03ba targeting the PLA2 receptor","volume":"23","author":"Debiec","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2\u20133","key":"10.1016\/j.clim.2022.108976_bb0240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb0245","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s00018-007-7497-9","article-title":"Extended and bent conformations of the mannose receptor family","volume":"65","author":"Llorca","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0250","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1074\/jbc.271.1.250","article-title":"Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2","volume":"271","author":"Zvaritch","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061669","article-title":"An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor","volume":"8","author":"Behnert","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0260","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0265","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2022.108976_bb0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.biochi.2015.08.007","article-title":"Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy","volume":"118","author":"Seitz-Polski","year":"2015","journal-title":"Biochimie"},{"issue":"40","key":"10.1016\/j.clim.2022.108976_bb0275","doi-asserted-by":"crossref","first-page":"13146","DOI":"10.1021\/bi00040a028","article-title":"Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2","volume":"34","author":"Ancian","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.clim.2022.108976_bb0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-6980(02)00022-9","article-title":"Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2","volume":"68\u201369","author":"Hanasaki","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.clim.2022.108976_bb0285","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.biochem.76.062405.154007","article-title":"Biochemistry and physiology of mammalian secreted phospholipases A2","volume":"77","author":"Lambeau","year":"2008","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/embor.2008.255","article-title":"The M-type receptor PLA2R regulates senescence through the p53 pathway","volume":"10","author":"Augert","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.clim.2022.108976_bb0295","doi-asserted-by":"crossref","first-page":"1936372","DOI":"10.1155\/2017\/1936372","article-title":"Recent progress in deciphering the etiopathogenesis of primary membranous nephropathy","volume":"2017","author":"Kronbichler","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0300","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.200206062","article-title":"Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication","volume":"159","author":"Tan","year":"2002","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0305","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcp.21990","article-title":"Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation","volume":"222","author":"Wang","year":"2010","journal-title":"J. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.clim.2022.108976_bb0310","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"372","author":"G\u00f6del","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2022.108976_bb0315","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2022.108976_bb0320","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0325","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/gcc.22440","article-title":"THSD7A expression in human cancer","volume":"56","author":"Stahl","year":"2017","journal-title":"Genes Chromosom. Cancer"},{"issue":"8","key":"10.1016\/j.clim.2022.108976_bb0330","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2012090913","article-title":"Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency","volume":"24","author":"Takahashi","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2022.108976_bb0335","series-title":"Autoimmunity in Membranous Nephropathy Targets Aldose Reductase and SOD2","first-page":"507","author":"Prunotto","year":"2010"},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0340","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J. Proteome"},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0345","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.kint.2015.12.057","article-title":"Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis","volume":"89","author":"Ryan","year":"2016","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb0350","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1681\/ASN.2017020178","article-title":"PLA2R and THSD7A: disparate paths to the same disease?","volume":"28","author":"Beck","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6457","key":"10.1016\/j.clim.2022.108976_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.289.6457.1500","article-title":"Familial membranous nephropathy","volume":"289","author":"Short","year":"1984","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0360","first-page":"193","article-title":"Familial idiopathic membranous glomerulonephritis","volume":"5","author":"Vasmant","year":"1984","journal-title":"Int. J. Pediatr. Nephrol."},{"issue":"8146","key":"10.1016\/j.clim.2022.108976_bb0365","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(79)92118-4","article-title":"Strong association between idiopathic membranous nephropathy and HLA-DRW3","volume":"2","author":"Klouda","year":"1979","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0370","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-0039.1982.tb00350.x","article-title":"HLA-DR3 and idiopathic membranous nephritis (IMN) association","volume":"20","author":"Le Petit","year":"1982","journal-title":"Tissue Antigens"},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0375","first-page":"15","article-title":"Immunogenetics and immunopathology of human primary membranous glomerulonephritis: HLA-A, B, DR antigens; functional activity of splenic macrophage Fc-receptors and peripheral blood T-lymphocyte subpopulations","volume":"22","author":"Berthoux","year":"1984","journal-title":"Clin. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0380","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-0039.1989.tb01741.x","article-title":"A DQA1 allele is strongly associated with idiopathic membranous nephropathy","volume":"34","author":"Vaughan","year":"1989","journal-title":"Tissue Antigens"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2022.108976_bb0385","first-page":"42","article-title":"HLA antigen and gene polymorphisms and haplotypes established by family studies in membranous nephropathy","volume":"7","author":"Dyer","year":"1992","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.clim.2022.108976_bb0390","first-page":"S13","article-title":"Molecular mapping of the HLA class II region in HLA-DR3 associated idiopathic membranous nephropathy","volume":"39","author":"Sacks","year":"1993","journal-title":"Kidney Int. Suppl."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0395","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1399-0039.1997.tb02855.x","article-title":"Idiopathic and secondary membranous nephropathy and polymorphism at TAP1 and HLA-DMA loci","volume":"50","author":"Chevrier","year":"1997","journal-title":"Tissue Antigens"},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0400","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0405","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0410","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1423-0127-17-81","article-title":"Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan","volume":"17","author":"Liu","year":"2010","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0415","doi-asserted-by":"crossref","first-page":"c253","DOI":"10.1159\/000320194","article-title":"Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy","volume":"117","author":"Kim","year":"2011","journal-title":"Nephron. Clin. Pract."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0420","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0425","first-page":"325","article-title":"Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies","volume":"32","author":"Sekula","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0430","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1681\/ASN.2016060644","article-title":"HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-related membranous nephropathy","volume":"28","author":"Le","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0435","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2022.108976_bb0440","doi-asserted-by":"crossref","first-page":"38189","DOI":"10.1038\/srep38189","article-title":"High-density association mapping and interaction analysis of PLA2R1 and HLA regions with idiopathic membranous nephropathy in Japanese","volume":"6","author":"Thiri","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0445","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: an update","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin. Immunopathol."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0450","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0455","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000090706","article-title":"Tumor necrosis factor-alpha gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis","volume":"26","author":"Bantis","year":"2006","journal-title":"Am. J. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0460","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.ki.5002054","article-title":"TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset\/occurrence of idiopathic membranous nephropathy","volume":"71","author":"Thibaudin","year":"2007","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0465","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1523-1755.1998.00833.x","article-title":"Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis","volume":"53","author":"Honkanen","year":"1998","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0470","first-page":"1444","article-title":"Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy","volume":"146","author":"Neale","year":"1995","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.clim.2022.108976_bb0475","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF02953018","article-title":"TNF-\u03b1 induces dyscohesion of epithelial cells. Association with disassembly of actin filaments","volume":"3","author":"Tabibzadeh","year":"1995","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0480","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.mnh.0000165885.85803.a8","article-title":"The slit diaphragm: a signaling platform to regulate podocyte function","volume":"14","author":"Huber","year":"2005","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"9\u201310","key":"10.1016\/j.clim.2022.108976_bb0485","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cca.2010.02.004","article-title":"Association between genetic polymorphisms of the NPHS1 gene and membranous glomerulonephritis in the Taiwanese population","volume":"411","author":"Lo","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0490","first-page":"3166","article-title":"Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy","volume":"23","author":"Chen","year":"2008","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0495","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3892\/mmr.2014.1903","article-title":"Impact of the 4G\/5G polymorphism in the plasminogen activator inhibitor-1 gene on primary nephrotic syndrome","volume":"9","author":"Luo","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0500","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3109\/0886022X.2010.516857","article-title":"Effect of IL-6 C-572G polymorphism on idiopathic membranous nephropathy risk in a Han Chinese population","volume":"32","author":"Chen","year":"2010","journal-title":"Ren. Fail."},{"issue":"21\u201322","key":"10.1016\/j.clim.2022.108976_bb0505","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.cca.2011.06.020","article-title":"Association of STAT4 polymorphisms with susceptibility to primary membranous glomerulonephritis and renal failure","volume":"412","author":"Chen","year":"2011","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0510","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3109\/0886022X.2013.828264","article-title":"Toll-like receptor 9 SNPs are susceptible to the development and progression of membranous glomerulonephritis: 27 years follow-up in Taiwan","volume":"35","author":"Chen","year":"2013","journal-title":"Ren. Fail."},{"issue":"22","key":"10.1016\/j.clim.2022.108976_bb0515","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMoa1013792","article-title":"Early-childhood membranous nephropathy due to cationic bovine serum albumin","volume":"364","author":"Debiec","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0520","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.biotechadv.2005.05.008","article-title":"Effects of food processing on the stability of food allergens","volume":"23","author":"Sathe","year":"2005","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.clim.2022.108976_bb0525","series-title":"Cons\u00e9quences des traitements thermiques et de la formulation sur la structure et l \u2019 allerg\u00e9nicit\u00e9 des prot\u00e9ines alimentaires Consequences of heat treatment and processing of food on the structure and allergenicity of component proteins","first-page":"13","author":"Sanchez","year":"2003"},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0530","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","article-title":"Idiopathic nephrotic syndrome and atopy: is there a common link?","volume":"54","author":"Abdel-Hafez","year":"2009","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0535","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1529-1049(02)00049-1","article-title":"Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders","volume":"2","author":"Richards","year":"2002","journal-title":"Clin. Appl. Immunol. Rev."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0540","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/mgme.1999.2894","article-title":"Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models","volume":"68","author":"Brooks","year":"1999","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0545","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","article-title":"Immune responses to therapeutic proteins in humans\u2013clinical significance, assessment and prediction","volume":"3","author":"Koren","year":"2002","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0550","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0555","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1681\/ASN.2013030290","article-title":"Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy","volume":"25","author":"Debiec","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"20","key":"10.1016\/j.clim.2022.108976_bb0560","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1056\/NEJM198105143042006","article-title":"Studies of immune-complex glomerulonephritis mediated by human thyroglobulin","volume":"304","author":"Jordan","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0565","first-page":"291","article-title":"Membranous glomerulonephritis (MGN)","volume":"13","author":"H\u00f6rl","year":"2000","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0570","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000077065","article-title":"Hepatitis B virus-associated nephropathy","volume":"24","author":"Bhimma","year":"2004","journal-title":"Am. J. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0575","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2169\/internalmedicine.49.2812","article-title":"Membranous nephropathy associated with chronic hepatitis B occurring in a short period after acute hepatitis B virus infection","volume":"49","author":"Nakahara","year":"2010","journal-title":"Intern. Med."},{"issue":"7","key":"10.1016\/j.clim.2022.108976_bb0580","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.10611110","article-title":"Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab","volume":"6","author":"Guiard","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0585","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ajkd.2010.03.010","article-title":"Immunoglobulin deposition disease with a membranous pattern and a circulating monoclonal immunoglobulin G with charge-dependent aggregation properties","volume":"56","author":"de Seigneux","year":"2010","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"10.1016\/j.clim.2022.108976_bb0590","series-title":"Regulation in the activation pathways","first-page":"41","article-title":"Chapter 3 - Regulation in the activation pathways","author":"Morgan BP","year":"1999"},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0595","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.semnephrol.2013.08.008","article-title":"Complement regulation in renal disease models","volume":"33","author":"Naik","year":"2013","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.clim.2022.108976_bb0600","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0605","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ng1890","article-title":"A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration","volume":"38","author":"Hughes","year":"2006","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0610","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0615","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.1987.179","article-title":"Epidemiology of idiopathic glomerular disease: a prospective study","volume":"32","author":"Tiebosch","year":"1987","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.0019-2805.2001.01341.x","article-title":"IgG4 breaking the rules","volume":"105","author":"Aalberse","year":"2002","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0625","first-page":"881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. \u2013 Eur. Ren. Assoc."},{"key":"10.1016\/j.clim.2022.108976_bb0630","series-title":"Antiphospholipase A 2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy","first-page":"1735","author":"Hofstra","year":"2012"},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0635","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2004121098","article-title":"Cellular response to injury in membranous nephropathy","volume":"16","author":"Nangaku","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0640","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1681\/ASN.2005010096","article-title":"Contrasting roles of complement activation and its regulation in membranous nephropathy","volume":"16","author":"Cunningham","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0645","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","article-title":"Membrane attack by complement: the assembly and biology of terminal complement complexes","volume":"51","author":"Tegla","year":"2011","journal-title":"Immunol. Res."},{"issue":"6\u20137","key":"10.1016\/j.clim.2022.108976_bb0650","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molimm.2004.04.007","article-title":"Cell signals transduced by complement","volume":"41","author":"Bohana-Kashtan","year":"2004","journal-title":"Mol. Immunol."},{"issue":"41","key":"10.1016\/j.clim.2022.108976_bb0655","doi-asserted-by":"crossref","first-page":"29977","DOI":"10.1074\/jbc.M703742200","article-title":"Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex","volume":"282","author":"Moskovich","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0660","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/ki.1995.496","article-title":"Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy","volume":"48","author":"Kon","year":"1995","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0665","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/ki.2009.389","article-title":"Endoplasmic reticulum stress in proteinuric kidney disease","volume":"77","author":"Cybulsky","year":"2010","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0670","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ki.2012.390","article-title":"The intersecting roles of endoplasmic reticulum stress, ubiquitin-proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease","volume":"84","author":"Cybulsky","year":"2013","journal-title":"Kidney Int."},{"issue":"13","key":"10.1016\/j.clim.2022.108976_bb0675","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.jprot.2012.04.016","article-title":"Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis","volume":"75","author":"Wang","year":"2012","journal-title":"J. Proteome"},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0680","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/path.2446","article-title":"A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies","volume":"217","author":"Meyer-Schwesinger","year":"2009","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0685","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajpath.2011.01.017","article-title":"Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy","volume":"178","author":"Meyer-Schwesinger","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0690","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0695","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-017-0451-5","article-title":"Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases","volume":"31","author":"Radice","year":"2018","journal-title":"J. Nephrol."},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb0700","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","article-title":"Diagnostic role of renal biopsy in PLA(2)R1-antibody-positive patients with nephrotic syndrome","volume":"32","author":"Wiech","year":"2019","journal-title":"Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc"},{"key":"10.1016\/j.clim.2022.108976_bb0705","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fmed.2019.00241","article-title":"Immune-monitoring disease activity in primary membranous nephropathy","volume":"6","author":"Cravedi","year":"2019","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0710","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000500456","article-title":"Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy","volume":"44","author":"Huang","year":"2019","journal-title":"Kidney Blood Press. Res."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN108602","article-title":"Anti-PLA2R-associated membranous nephropathy: A review with emphasis on diagnostic testing methods","volume":"84","author":"VanBeek","year":"2015","journal-title":"Clin. Nephrol."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0720","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40620-018-0533-z","article-title":"Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy","volume":"31","author":"Tampoia","year":"2018","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0725","first-page":"109","article-title":"Anti-PLA\u2082R antibodies in membranous nephropathy: ready for routine clinical practice?","volume":"70","author":"Hofstra","year":"2012","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.clim.2022.108976_bb0730","series-title":"And its clinical usefulness in patients with membranous glomerulonephritis","first-page":"2526","author":"Hoxha","year":"2011"},{"key":"10.1016\/j.clim.2022.108976_bb0735","first-page":"2018","article-title":"Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management","author":"Pozdzik","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.clim.2022.108976_bb0740","first-page":"2014","article-title":"Antiphospholipase A2 receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy","author":"Behnert","year":"2014","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0745","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A 2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.clim.2022.108976_bb0750","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0755","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10157-014-1054-2","article-title":"Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy","volume":"19","author":"Akiyama","year":"2015","journal-title":"Clin. Exp. Nephrol."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2022.108976_bb0760","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/nep.12458","article-title":"Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins","volume":"20","author":"Saito","year":"2015","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"10.1016\/j.clim.2022.108976_bb0765","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0770","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Jourde-Chiche","year":"2019","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0775","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0780","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2249.1999.01080.x","article-title":"Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN)","volume":"118","author":"Wakui","year":"1999","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0785","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10157-016-1235-2","article-title":"Circulating antibodies to \u03b1-enolase and phospholipase A(2) receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy","volume":"21","author":"Kimura","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0790","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin. Nephrol."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0795","first-page":"479","article-title":"Diagnosis and management of nephrotic syndrome in adults","volume":"93","author":"Kodner","year":"2016","journal-title":"Am. Fam. Physician"},{"issue":"8","key":"10.1016\/j.clim.2022.108976_bb0800","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","article-title":"An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis","volume":"26","author":"Hoxha","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"30","key":"10.1016\/j.clim.2022.108976_bb0805","article-title":"Membranous nephropathy associated with immunological disorder-related liver disease A retrospective study of 10 cases","volume":"94","author":"Dauvergne","year":"2015","journal-title":"Med. (United States)"},{"issue":"7","key":"10.1016\/j.clim.2022.108976_bb0810","first-page":"1839","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.clim.2022.108976_bb0815","series-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","first-page":"1137","author":"Qin","year":"2011"},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0820","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod. Pathol. an Off. J. United States Can. Acad. Pathol. Inc"},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174501","article-title":"Dissecting the relationships of IgG subclasses and complements in membranous lupus nephritis and idiopathic membranous nephropathy","volume":"12","author":"Na","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0830","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1523-1755.2002.00124.x","article-title":"Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy","volume":"61","author":"Torres","year":"2002","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.clim.2022.108976_bb0835","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.2215\/CJN.04020411","article-title":"Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy","volume":"6","author":"van den Brand","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0840","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4S","key":"10.1016\/j.clim.2022.108976_bb0845","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0850","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy--a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.clim.2022.108976_bb0855","first-page":"1862","article-title":"Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy","volume":"30","author":"Hoxha","year":"2015","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0860","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CNP72366","article-title":"Optimal blood pressure control versus additional immunosuppressive therapy in idiopathic membranous nephropathy \u2013 a retrospective analysis","volume":"72","author":"Dikow","year":"2009","journal-title":"Clin. Nephrol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0865","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0870","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1523-1755.2004.00518.x","article-title":"Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan","volume":"65","author":"Shiiki","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0875","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000437288","article-title":"Management of membranous nephropathy in Asia","volume":"1","author":"Xu","year":"2015","journal-title":"Kidney Dis."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0880","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide","volume":"50","author":"Branten","year":"2007","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"9868","key":"10.1016\/j.clim.2022.108976_bb0885","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0890","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0895","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1056\/NEJM198901263200403","article-title":"A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy","volume":"320","author":"Cattran","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0900","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0905","first-page":"467","article-title":"Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus","volume":"30","author":"Caro","year":"2015","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. \u2013 Eur. Ren. Assoc."},{"issue":"8","key":"10.1016\/j.clim.2022.108976_bb0910","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0915","first-page":"CD004293","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb0920","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0925","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb0930","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184398","article-title":"Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis","volume":"12","author":"Ren","year":"2017","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.clim.2022.108976_bb0935","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMcibr0806881","article-title":"Proteinuria and Immunity \u2014 an Overstated Relationship?","volume":"359","author":"Mathieson","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb0940","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb0945","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.05231008","article-title":"Rituximab therapy for membranous nephropathy: a systematic review","volume":"4","author":"Bomback","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0950","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0955","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0960","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000450659","article-title":"Rituximab in membranous nephropathy: not all studies are created equal","volume":"135","author":"Cravedi","year":"2017","journal-title":"Nephron"},{"issue":"13","key":"10.1016\/j.clim.2022.108976_bb0965","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5414\/CNP88FX07","article-title":"Rituximab for the treatment of membranous nephropathy: a single-center experience","volume":"88","author":"Ale\u0161 Rigler","year":"2017","journal-title":"Clin. Nephrol."},{"issue":"10","key":"10.1016\/j.clim.2022.108976_bb0970","first-page":"1691","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"3\u20134","key":"10.1016\/j.clim.2022.108976_bb0975","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000368589","article-title":"Rituximab in primary membranous nephropathy: first-line therapy, why not?","volume":"128","author":"Cravedi","year":"2014","journal-title":"Nephron. Clin. Pract."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb0980","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","article-title":"Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and Rituximab","volume":"1","author":"Waldman","year":"2016","journal-title":"Kidney Int. Rep."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb0985","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2215\/CJN.04120609","article-title":"Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation","volume":"5","author":"Sprangers","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.clim.2022.108976_bb0990","doi-asserted-by":"crossref","first-page":"18","DOI":"10.15171\/jrip.2017.04","article-title":"Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy","volume":"6","author":"Cheungpasitporn","year":"2016","journal-title":"J. Ren. Inj. Prev."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb0995","first-page":"657","article-title":"Rituximab-induced urticarial dermatitis during the treatment of membranous nephropathy","volume":"28","author":"Radhakrishnan","year":"2017","journal-title":"Saudi J. kidney Dis. Transplant. an Off. Publ. Saudi Cent. Organ Transplantation, Saudi Arab."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb1000","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1046\/j.1523-1755.2002.00214.x","article-title":"Mycophenolate mofetil treatment for primary glomerular diseases","volume":"61","author":"Choi","year":"2002","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.clim.2022.108976_bb1005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb1010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044330","article-title":"Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults","volume":"7","author":"Xie","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb1015","first-page":"1351","article-title":"Efficacy and safety of \u2018rescue therapy\u2019 with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study","volume":"22","author":"Segarra","year":"2007","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"issue":"6","key":"10.1016\/j.clim.2022.108976_bb1020","doi-asserted-by":"crossref","first-page":"637","DOI":"10.5414\/CNP71637","article-title":"Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24","volume":"71","author":"Rauen","year":"2009","journal-title":"Clin. Nephrol."},{"issue":"2","key":"10.1016\/j.clim.2022.108976_bb1025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am. J. kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"3","key":"10.1016\/j.clim.2022.108976_bb1030","first-page":"350","article-title":"Bortezomib as a novel approach to early recurrent membranous glomerulonephritis after kidney transplant refractory to combined conventional rituximab therapy","volume":"15","author":"Barbari","year":"2017","journal-title":"Exp. Clin. Transplant. Off. J. Middle East Soc. Organ Transplant."},{"issue":"5","key":"10.1016\/j.clim.2022.108976_bb1035","first-page":"113","article-title":"Membranous glomerulonephritis (MGN), ongoing studies","volume":"34","author":"La Manna","year":"2017","journal-title":"G. Ital. di Nefrol. organo Uff. della Soc. Ital. di Nefrol."},{"issue":"9","key":"10.1016\/j.clim.2022.108976_bb1040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:06:35Z","timestamp":1761494795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":208,"alternative-id":["S1521661622000572"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.108976","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting immunological and clinical aspects of membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.108976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108976"}}